VAXX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States...

Stats
Dagens volum	56.12M
Gjennomsnittsvolum	1.07M
Markedsverdi	19.85M
EPS	$0 ( 2024-03-25 )
Neste inntjeningsdato	( $-0.100 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.310
ATR14	$0.00100 (0.71%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-01	Ray Sumita	Buy	425 000	Employee Stock option (right to buy)
2023-11-03	Paula Molina Rene	Buy	0
2023-10-02	Powchik Peter	Buy	159 744	Stock option (right to buy)
2023-10-01	Ray Sumita	Buy	0
2023-09-06	Prime Movers Lab Fund I Lp	Sell	5 308	Class A Common Stock

INSIDER POWER
55.10
Last 91 transactions
Buy: 6 350 518 \| Sell: 2 608 586

Volum Korrelasjon

Lang: 0.34 (neutral)

Kort: 0.90 (very strong)

Signal:(65.212) Expect same movement, but be aware

Vaxxinity, Inc. Korrelasjon

10 Mest positive korrelasjoner
DUNE	0.92
CIIG	0.918
ONEM	0.906
LGVC	0.902
POAI	0.902
YVR	0.901
MEUSW	0.894
BBCP	0.886
MRNS	0.876
VYGR	0.876

10 Mest negative korrelasjoner
NYMX	-0.905
RANI	-0.903
CHCI	-0.903
GAIA	-0.898
THCP	-0.886
GRIN	-0.879
ABIO	-0.879
CSTE	-0.873
CATB	-0.869
CADL	-0.844

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Vaxxinity, Inc. Korrelasjon - Valuta/Råvare

0.00
( neutral )

-0.19
( neutral )

Vaxxinity, Inc. Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$-2.23M (0.00 %)
EPS:	$-0.450

FY	2023
Omsetning:	$0
Bruttogevinst:	$-2.23M (0.00 %)
EPS:	$-0.450

FY	2022
Omsetning:	$0
Bruttogevinst:	$-1.68M (0.00 %)
EPS:	$-0.600

FY	2021
Omsetning:	$66 000.00
Bruttogevinst:	$-1.87M (-2 834.85 %)
EPS:	$-1.100

Financial Reports:

No articles found.

Vaxxinity, Inc.

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.